Investing to meet the scientific challenges of HIV/AIDS.
Despite extraordinary scientific advances over more than twenty-five years, the human immunodeficiency virus (HIV) continues to exact an enormous toll worldwide. Given the limitations of current HIV treatment and prevention interventions and the financial and logistical impediments to delivering them, new and potentially transforming interventions are needed if the HIV/AIDS pandemic is to be significantly slowed. Serious scientific challenges remain in the realm of developing potentially curative therapies and a safe and effective HIV vaccine, and in developing, assessing, and validating other new prevention modalities. Substantial funding of the research enterprise must be maintained.
Fauci
Anthony S
AS
National Institute ofAllergy and Infectious Diseases at National Institutes of Health in Bethesda, Maryland, USA.
Folkers
Gregory K
GK
D016915:AIDS Vaccines; D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D014943:Global Health; D015658:HIV Infections / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D005102:Health Expenditures; D006801:Humans; D058873:Pandemics; D012109:Research Support as Topic
D016915:AIDS Vaccines; D044966:Anti-Retroviral Agents